Conference Coverage EHA 2023 – Focus on Multiple Myeloma (Global)
The latest therapeutic developments in multiple myeloma – how will they change our approach to treatment patterns?
Faculty Members
Irene Ghobrial, MD
Dana-Farber Cancer Institute, Boston, MA, USA
Hermann Einsele, MD, FRCP
University Hospital Würzburg, Germany
Keith Stewart, MB, ChB
Princess Margaret Cancer Centre, Toronto, ON, Canada
Gareth Morgan, MD, PhD, FRCP, FRCPath
NYU Langone Health, New York, NY, USA
Xavier Leleu, MD, PhD
Poitiers University Hospital, Poitiers, France
Niels van de Donk, MD, PhD
Amsterdam UMC, Amsterdam, the Netherlands
REPORT TOPICS
- Treatment in Transplant-Eligible and Smoldering Multiple Myeloma
- NDMM: Transplant-Ineligible Multiple Myeloma
- Relapsed/Refractory Multiple Myeloma: Small Molecules
- Relapsed/Refractory Multiple Myeloma: Antibodies and Bispecifics
- Relapsed/Refractory Multiple Myeloma: CAR T